Are Theravance And Mylan's US COPD Chances Bigger Than First Thought?

With Theravance Biopharma's promising once-daily nebulized LAMA bronchodilator, partnered with Mylan, set for FDA filing later this year, analysts say the product might have a bigger market than initially presumed, and are now looking beyond to the firm's other pipeline activities.

COPD
Mylan Says Revefenacin Generated Good Phase III Safety And Tolerability Data • Source: Shutterstock

Partners Mylan NV and Theravance Biopharma Inc. say they will submit their nebulized once-daily LAMA respiratory drug revefenacin for regulatory approval after receiving good Phase III safety and tolerability data for the long-acting muscarinic antagonist (LAMA) in treating chronic obstructive pulmonary disease (COPD).

The duo, which have a strategic collaboration to develop and commercialize revefenacin products for COPD and other respiratory diseases, said...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D